Literature DB >> 17050802

Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach.

Xuemin Jiang1, Elaine Y L Blair, Andrew J McLachlan.   

Abstract

Systematic evidence regarding herb-drug interactions is lacking. This study investigated herb-drug interactions with warfarin. S-warfarin concentration and response (prothrombin complex activity) data from healthy subjects (n = 24) who received a single warfarin dose (25 mg) and either St John's wort, Asian ginseng, Ginkgo biloba, or ginger were analyzed using a population pharmacokinetic-pharmacodynamic modeling approach. The ratio of S-warfarin apparent clearance (CL/F) compared to control was 1.39 +/- 0.06 and 1.14 +/- 0.04 after St John's wort and Asian ginseng pretreatment, respectively. Other pharmacokinetic and pharmacodynamic parameters were unaffected. Coadministration of St John's wort significantly increased S-warfarin CL/F, whereas treatment with Asian ginseng produced only a moderate increase in CL/F. Ginkgo and ginger did not affect the pharmacokinetics of warfarin in healthy subjects. None of the herbs studied had a direct effect on warfarin pharmacodynamics. Studies in anticoagulated patients are warranted to assess the clinical significance of these herb-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050802     DOI: 10.1177/0091270006292124

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  19 in total

Review 1.  Interaction between warfarin and Chinese herbal medicines.

Authors:  Yan Ting Chua; Xiang Ling Ang; Xi Ming Zhong; Kei Siong Khoo
Journal:  Singapore Med J       Date:  2015-01       Impact factor: 1.858

2.  Response to R-warfarin anticoagulant effect.

Authors:  Ling Xue; Nick Holford; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2017-07-23       Impact factor: 4.335

Review 3.  What do most erectile dysfunction guidelines have in common? No evidence-based discussion or recommendation of heart-healthy lifestyle changes and/or Panax ginseng.

Authors:  Mark A Moyad; Kwangsung Park
Journal:  Asian J Androl       Date:  2012-09-24       Impact factor: 3.285

Review 4.  Therapeutic potential of ginseng in the management of cardiovascular disorders.

Authors:  Morris Karmazyn; Melissa Moey; Xiaohong Tracey Gan
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

5.  Warfarin, St John's wort and INR.

Authors:  Angela Cattanach; Siboniso Sibindi
Journal:  Aust Prescr       Date:  2016-04-01

6.  Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.

Authors:  Ling Xue; Nick Holford; Xiao-Liang Ding; Zhen-Ya Shen; Chen-Rong Huang; Hua Zhang; Jing-Jing Zhang; Zhe-Ning Guo; Cheng Xie; Ling Zhou; Zhi-Yao Chen; Lin-Sheng Liu; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2016-11-25       Impact factor: 4.335

Review 7.  Pharmacokinetic Drug Interactions with Panax ginseng.

Authors:  Meenakshi R Ramanathan; Scott R Penzak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

8.  Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Stephen Wise; Danny Soon; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-26       Impact factor: 2.745

9.  Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects.

Authors:  M I Mohammed Abdul; X Jiang; K M Williams; R O Day; B D Roufogalis; W S Liauw; H Xu; A J McLachlan
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

10.  Encouraging the move towards predictive population models for the obese using propofol as a motivating example.

Authors:  Sarah C McLeay; Glynn A Morrish; Carl M Kirkpatrick; Bruce Green
Journal:  Pharm Res       Date:  2009-04-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.